bluuebunny/crossref_metadata_2025_split huggingface dataset:
715-P: How Frequently Do People with Diabetes Use a Digital Diabetes Logbook and How Satisfied Are They with It?
Authors: HERMANNS NORBERT , EHRMANN DOMINIC , SILBERMANN STEPHAN , KOBER JOHANNA , VESPER IRIS , FINKE-GRÖNE KATHARINA , ROOS TIMM , BINGOL EZGI , KULZER BERNHARD 
Published: June 2023

A randomized controlled trial (RCT) was conducted to evaluate the efficacy of a digital diabetes logbook (mySugr) to help with diabetes self-management. Frequency of use as well as satisfaction with the app were assessed. A total of 424 people were included in the RCT with 282 being randomized to the intervention group using the app for 3 months (2:1 randomization) (age: 51.2±14.6 years; 13.1% type 1, 66.7% type 2, 20.2% gestational diabetes). Frequency of use was assessed with user data from the pseudonymized study server. Satisfaction with mySugr was assessed with an adapted version of the Mobile App Rating Scale (MARS). Mean MARS scores were calculated (range: 1-5) with higher scores indicating higher satisfaction.
User data from 249 participants of the intervention group (88.3%) were analyzable. The app was used on a median of 92.6% (IQR: 57.7 - 100%) of the study days (median study duration: 91 [IQR: 84-96] days). Over the study duration, participants logged 3.1±2.5 blood glucose values. Satisfaction was very high with a mean MARS score of 4.3±0.7. 64.7% of participants agreed that the app is appealing for people with diabetes and 82.5% agreed that the app is easy to use. Satisfaction was highest in women with gestational diabetes, followed by people with type 1 and people with type 2 diabetes (4.5±0.5 vs. 4.3±0.6 vs. 4.2±0.7; p=0.037). Higher satisfaction was associated with higher percentage of days with app use (r=0.23, p&lt;0.001), higher logging frequency (r=0.20, p=0.002) and less problems with the app (r=-0.20, p=0.001). Those who contacted mySugr support when they had problems were significantly more satisfied than those who did not contact support when they had problems (4.6±0.4 vs. 3.8±0.7, p=0.023).
Participants randomized to using mySugr for 3 months (no prior app use) were highly satisfied with the app. Frequency of use of the app across the study period was very high. Satisfaction was high in all diabetes types with women with gestational diabetes having the highest satisfaction.

Disclosure
N.Hermanns: Advisory Panel; Insulet Corporation, Research Support; Sanofi-Aventis Deutschland GmbH, Roche Diagnostics, Becton, Dickinson and Company, Speaker's Bureau; Dexcom, Inc., Berlin-Chemie AG. D.Ehrmann: Advisory Panel; Roche Diabetes Care, mySugr, Dexcom, Inc., Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. S.Silbermann: Employee; Roche Diabetes Care. J.Kober: Employee; mySugr. I.Vesper: None. K.Finke-gröne: None. T.Roos: None. E.Bingol: Employee; Roche Diabetes Care. B.Kulzer: Advisory Panel; Berlin-Chemie AG, Abbott Diabetes, Bayer Inc., Dexcom, Inc., Novo Nordisk, Insulet Corporation, embecta, Research Support; Sanofi, Roche Diabetes Care.

Funding
Roche Diabetes Care GmbH (DC000097)
719-P: Feasibility and Acceptability of the Quality of Life, Burden of Treatment, Safety, and Avoidance of Future Events Agenda Setting Kit (QBSAFE ASK)
Authors: HAIDER SHANZAY , GONZALEZ LOPEZ CAROLINA , CLARK JENNIFER , GRAVHOLT DEREK L. , BRESLIN MAGGIE , BOEHMER KASEY , HARTASANCHEZ SANDRA A. , SANCHEZ BRIANNA B.M. , MONTORI VICTOR M. , LIPSKA KASIA J. 
Published: June 2023

Objectives: Diabetes care has traditionally focused on target A1c, leaving other patient goals and needs under-addressed. We assessed the feasibility and acceptability of conversation cards (QBSAFE agenda setting kit) during routine clinic visits.
Methods: We recruited clinicians and their patients with diabetes into a single-arm intervention study. The intervention consisted of a set of 14 conversation cards (QBSAFE ASK) describing diabetes-related topics. The cards were presented to patients and asked to select 0-3 cards for discussion. Clinicians and patients completed post-encounter acceptability surveys. Feasibility was assessed based on participant enrollment, time to enrollment, and percent who completed study procedures. Encounters were recorded and analyzed to describe the cards selected and clinician responses to the cards.
Results: A total of 85 patients (63yo ± 14.7, 43.5% female, and 84.5% white) and 7 clinicians were recruited over 5 months. Among 85 patients, 68.2% completed all study procedures. Most patients (63.8%) agreed the cards helped discuss their situation, 77.6% agreed other patients could benefit from them, but only 37.9% would use the cards again. Clinicians felt confident responding to issues raised by the cards during 89.9% of encounters and would recommend the cards to their colleagues (82.4%). Based on video analysis, 83.3% of patients selected at least 1 card, with the common being “I have difficulties with diet and exercise” (34.5%). Clinicians most often responded by asking elaborating questions (81.8% of encounters) followed by change in treatment (34.5%). The tool often elicited collaborative conversations between clinicians and patients (58% of encounters).
Conclusions: QBSAFE ASK can be feasibly implemented into clinical care, is generally acceptable, and holds promise in helping patients discuss their situation with clinicians and in eliciting collaborative problem-solving.

Disclosure
S.Haider: None. K.J.Lipska: Other Relationship; UpToDate. C.Gonzalez lopez: None. J.Clark: None. D.L.Gravholt: None. M.Breslin: None. K.Boehmer: None. S.A.Hartasanchez: None. B.B.M.Sanchez: None. V.M.Montori: None.

Funding
National Institute on Aging (5R21AG061427)
721-P: Mood and Sleep in Young Adults with Type 1 Diabetes
Authors: CARREON SAMANTHA A. , MINARD CHARLES G. , LYONS SARAH , STREISAND RANDI , TANG TRICIA S. , MCKAY SIRIPOOM , ANDERSON-THOMAS BARBARA J. , NOWAKOWSKI SARA , BUTLER ASHLEY , HILLIARD MARISA E. 
Published: June 2023

Introduction: Depression is linked with sleep problems and for people with T1D, mood concerns and sleep are associated with A1c. There are psychosocial and sleep challenges in young adulthood, yet their associations are unknown in racially/ethnically diverse young adults with T1D. We aimed to evaluate general mood and T1D-specific mood in relation to sleep in young adults with T1D, controlling for relevant medical and demographic factors. We hypothesized that depressive symptoms and T1D distress would explain the greatest variance in sleep outcomes.
Methods: Young adults with T1D (n=83, M age=19.9±1.3 yrs, M A1c=8.9±2.0%) self-reported on sleep, T1D distress, depressive symptoms, race/ethnicity, insurance status and device use at baseline of a behavioral trial. Hierarchical regression models evaluated factors related to sleep quality and duration.
Results: Participants reported M=7.1±1.4 (range: 4-12) hrs sleep/night and 28% described their sleep as fairly-very bad. As detailed in the Table, only greater diabetes distress was significantly associated with worse sleep quality. No factors significantly related to duration.
Conclusions: Despite sleeping near the target 7-9 hrs/night, the centrality of diabetes distress for young adults’ perceived sleep quality highlights its importance beyond commonly related medical and demographic factors. Clinical attention to T1D-specific mood concerns may benefit sleep health during young adulthood.

Disclosure
S.A.Carreon: None. M.E.Hilliard: None. C.G.Minard: None. S.Lyons: None. R.Streisand: None. T.S.Tang: Research Support; Juvenile Diabetes Research Foundation (JDRF), Speaker's Bureau; Abbott Diabetes, Insulet Corporation. S.Mckay: None. B.J.Anderson-thomas: None. S.Nowakowski: None. A.Butler: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK119246 to M.E.H.), (3R01DK119246-04S1 to M.E.H., S.A.C.)
722-P: The Value of Collaborative Parental Involvement in Diabetes Management for Youth with Type 1 Diabetes
Authors: ANIFOWOSHE KASHOPE I. , JASER SARAH S. 
Published: June 2023

Type 1 diabetes (T1D) is typically diagnosed during late childhood or early adolescence. Parents are often initially responsible for their child's diabetes management, which transfers to the child over time. The Collaborative Parent Involvement (CPI) Scale measures the child's perceived quality of parental involvement in their diabetes care. We examined the relationship between CPI and other key factors of child and adolescent T1D management: self-care, Diabetes Family Conflict (DFC), and Pediatric Quality of Life (PedsQL). Data were collected from participants in a randomized controlled trial which included adolescents with T1D (age 11-17) and their female caregivers. Participants completed baseline surveys, including the CPI, DFC, and PedsQL, as well as a parent- and self-report measure of how well the child manages their diabetes. HbA1c was extracted from adolescents’ medical charts. Bivariate correlations were used to assess relationships between CPI and other diabetes outcomes. Higher levels of collaborative parenting were associated with greater self- and parent-reports of perceived self-care (r= .23, .22, both p&lt;.01). In contrast, greater collaboration was associated with lower levels of child- and parent-reported diabetes-specific conflict (r= -.23, -.20, p&lt;.01, p&lt;.05). Higher levels of collaboration were also associated with higher quality of life (r= .45, p&lt;.01) and lower HbA1c (r= -.28, p&lt;.01). No significant differences in CPI scores were found related to child gender, race/ethnicity, diabetes device use, or between different income groups. Findings indicate that adolescents’ perceived quality of parental involvement is associated with several key factors of T1D management. While the quantity of parental involvement is often a targeted area in pediatric T1D care, clinicians and parents should also focus on the quality of involvement. Enhanced parent-child collaboration may help families handle the many stressors associated with T1D management.

Disclosure
K.I.Anifowoshe: None. S.S.Jaser: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK11545)
723-P: Patient-Reported Barriers to Continuous Glucose Monitor Usage
Authors: PARK JULIE J. , GUTTMANN-BAUMAN INES , CHUN ARUM , PANDHARPURKAR TEJAL H. , MULLIN RACHAEL 
Published: June 2023

Aims: What are patient reported barriers to continuous glucose monitor (CGM) use in the pediatric type 1 diabetes population?
Methods: Recruited patients with type 1 diabetes of ≥6 months at Harold Schnitzer Diabetes Health Center filled out a survey regarding their current glucose monitoring system. The survey incorporated the GMSS-T1D1 and qualitative sections to assess patient's satisfaction, experience, quality of life, and barriers of using CGM and standard glucometers (SGM). Caregivers of patients younger than 15 years were surveyed with verbal assent from patients who were ≥7 years. Duration of diabetes, A1c, and type of insurance were also studied.
Results: 114 patients were recruited with 69 patients completing the study. Ages ranged from 3 - 19 years, with a mean age of 12.6 years. 70% were CGM users and 30% SGM users. 64% of current SGM users had CGM use in the past. 28% of current CGM users reported difficulties using the CGM. Reported difficulties were grouped into categories; healthcare system related, physical, difficult to use, trust, and device malfunction. The most common difficulty among current CGM users was in regards to obtaining the device related to cost, delivery, and replacements. Past CGM users reported the same difficulty obtaining the device and difficulty using the device as top reasons for not using CGM. Overall current CGM users had higher satisfaction scores on the GMSS and better A1c than SGM users.
Conclusion: CGM users reported higher satisfaction with their device and better control of their diabetes. Current CGM users reported difficulties with cost, unreliable delivery of refills and replacements, and physical barriers including limited sites, pain and bleeding. Past CGM users reported additional barriers with device malfunction and not liking it.

Disclosure
J.J.Park: None. I.Guttmann-bauman: None. A.Chun: None. T.H.Pandharpurkar: None. R.Mullin: None.
725-P: Depressive Symptoms and Insomnia and Their Relationship with Lack of Adherence to Treatment and Metabolic Control in Patients with Type 2 Diabetes Mellitus
Authors: ESCOBAR MELISSA N. , RAMIREZ ANA I. , BUENO COLMAN ELVIO D. , BENITEZ ALDO , PALACIOS MAFALDA , JIMENEZ JORGE T. 
Published: June 2023

Aim: To determine the relationship between depressive symptoms and insomnia with therapeutic non-adherence and metabolic control in patients with T2DM.
Methods: Observational, descriptive, cross-sectional study with analytical component. Adult patients with DM2 treated in an Endocrinology Service of a University Hospital of Asunción-Paraguay from May to October 2022. The Morinsky-Green adherence questionnaires, the Insomnia Severity Index (ISI), the Patient Health Questionnaire 9 (PHQ-9) and predetermined questionnaire for clinical characteristics where used.
Results: 171 patients were studied. Women: 69%. Mean age 54.9 ± 11.8 years. Symptoms of depression occurred in 61.9%. 59% suffered insomnia. The 64.3% of patients had moderate non-adherence. The mean HbA1c was 8.08 ± 0.16 %. Inadequate metabolic control (HbA1c &gt;7%) was seen in 68% of patients. A relationship was found between depression and insomnia (p&lt;0,001), in addition to the fact that the worse adherence the more depressive symptoms (p&lt;0,001) and the more insomnia (p &lt;0.001).Patients with poor metabolic control have more depressive symptoms (p=0,005) and insomnia (p=0,009).

Conclusion: Depressive symptoms were significantly related to non-adherence to treatment and to worse metabolic control, but not the presence of insomnia without depressive symptoms.

Disclosure
M.N.Escobar: None. A.I.Ramirez: None. E.D.Bueno colman: None. A.Benitez: None. M.Palacios: Speaker's Bureau; Sanofi. J.T.Jimenez: None.
729-P: Metabolic Surgery for the Treatment of Type 2 Diabetes Mellitus in China—Five-Year Outcomes from a Prospective Multicenter Study
Authors: BAO YUQIAN , LIANG HUI , ZHANG PIN , WANG CUNCHUAN , JIANG TAO , ZHANG NENGWEI , ZHU JIANGFAN , YU HAOYONG , HAN JUNFENG , TU YINFANG , LIN SHIBO , ZHANG HONGWEI , YANG WAH , YANG JINGGE , CHEN SHU , FAN QING , MA YINGZHANG , MA CHIYE , WAGGONER JASON , TOKARSKI ALLISON , EDWARDS NATALIE , YANG TENGFEI , ZHANG RONGRONG , JIA WEIPING 
Published: June 2023

The prevalence of type 2 diabetes (T2D) among adults in China is 10.9%-13.2%. Multicenter, long-term, prospective studies evaluating bariatric/metabolic surgery in obese patients with T2D in China are limited. This prospective study evaluated the 5-year impact of laparoscopic Roux-en-Y gastric bypass (RYGB; n=76 subjects, mean [SD] age 36.4 [9.5], 52.6% women, mean [SD] BMI 34.6 [4.9] kg/m2, mean [SD] glycosylated hemoglobin A1c [HbA1c] 8.3% [1.7%], mean [SD] duration diabetes 3.7 [2.7]) and sleeve gastrectomy (SG; n=25 subjects, mean [SD] age 41.1 [10.8], 44.0% women, mean [SD] BMI 36.4 [6.0] kg/m2, mean [SD] HbA1c 7.5% [1.5%], mean [SD] duration diabetes 2.4 [2.4]) on T2D at six centers in China from August 2014-April 2021. According to the composite measure of glycemic control for metabolic surgeries as suggested by the American Society for Metabolic and Bariatric Surgery, among 62 subjects evaluable at five years (50 RYGB, 12 SG), complete remission occurred in 28.6% (27.5% RYGB, 33.3% SG), partial remission in 27.0% (29.4% RYGB, 16.7% SG), improvement in 30.2% (29.4% RYBG, 33.3% SG), no change in 9.5% (7.8% RYBG, 16.7% SG), and recurrence in 4.8% (5.9% RYGB). Significant 5-year reductions in HbA1c (RYGB -1.7±2.1%, SG -1.8±1.1%), body weight (RYGB -19.8±8.4 kg, SG -21.2±6.0 kg), and BMI (RYGB -7.1±3.1 kg/m2, SG -7.7±2.1 kg/m2) were observed (all p&lt;0.001). Five-year improvements in triglycerides and high-density lipoprotein cholesterol were also observed. Procedure-related serious adverse events occurred in 8 RYGB subjects (7.9%). To our knowledge, this is the first prospective, multicenter, 5-year study of bariatric/metabolic surgery in subjects with T2D in China. These data demonstrate that RYGB and SG achieved clinically meaningful, sustained impacts on T2D remission in many subjects for up to five years. Bariatric/metabolic surgery has enormous potential to provide a safe and effective option for appropriately selected subjects with T2D in China.

Disclosure
Y.Bao: None. Y.Tu: None. S.Lin: None. H.Zhang: None. W.Yang: None. J.Yang: None. S.Chen: None. Q.Fan: None. Y.Ma: None. C.Ma: None. J.Waggoner: Employee; Ethicon, Inc., Janssen Research & Development, LLC, Stock/Shareholder; Johnson & Johnson. H.Liang: None. A.Tokarski: Employee; Ethicon, Inc. N.Edwards: Consultant; Boston Scientific Corporation, EMD Serono, Inc., Ethicon, Inc., Johnson & Johnson, Becton, Dickinson and Company. T.Yang: None. R.Zhang: None. W.Jia: None. P.Zhang: None. C.Wang: None. T.Jiang: None. N.Zhang: None. J.Zhu: None. H.Yu: None. J.Han: None.

Funding
Ethicon, Inc.; Johnson & Johnson
730-P: Effects of Obstructive Sleep Apnea Treatment on Whole-Body and Adipose Tissue Insulin Sensitivity—Role of Senescence and Mitigation by Adjuvant Metformin Therapy
Authors: RODRIGUES SARA , DANTAS WAGNER S. , BEYL ROBBIE A. , HEBERT REBEKAH C. , GRIFFITH ISABELLA , TANKSLEY MAKAYLA , MADER EDWARD C. , KIRWAN JOHN P. , AXELROD CHRISTOPHER L. , RAVUSSIN ERIC , SINGH PRACHI 
Published: June 2023

Introduction: Obstructive sleep apnea (OSA) is a prevalent sleep disorder linked to high type 2 diabetes risk. Positive airway pressure (PAP) therapy is the standard of care for OSA, but it inconsistently improves glucose homeostasis. Senescent cells are common in adipose tissue (AT) of patients with OSA and may impair insulin signaling. However, the effects of PAP therapy on AT senescence are not known. Addition of metformin, an insulin-sensitizer with anti-senescent effects, may be a good adjuvant therapeutic strategy to improve glycemic control in patients with OSA.
Methods: We randomly assigned 16 nondiabetic participants with OSA (Mean± SD; age: 50.9 ± 6.7 y, BMI: 36.5 ± 2.9 kg/m2) in a 1:1 ratio to receive either 2g metformin or placebo daily along with PAP therapy for 3 months in a double-blind pilot study. Whole body and AT insulin sensitivity was determined by 2h oral glucose tolerance test (OGTT). AT biopsy was obtained to estimate tissue insulin signaling and senescence.
Results: The metformin and placebo groups had comparable age, BMI and OSA severity at baseline. PAP compliance was 38% and 75% in the metformin and placebo groups, respectively. Matsuda Index, glucose area under the curve (2h AUC), and free-fatty acid suppression at baseline and follow-up were not different in metformin or placebo treated groups. Compared to baseline, insulin AUC and insulin to glucose AUC ratio during OGTT was unchanged in the metformin but increased in the placebo group. Metformin, but not placebo, was associated with increased insulin mediated AKT phosphorylation and decreased senescence biomarkers (p21 and MCP1) in AT during the follow-up visit.
Conclusion: Metformin, as adjunct to PAP therapy, attenuated insulin rises during OGTT, improved AT insulin signaling, and lowered senescence biomarkers in OSA patients. Larger trials of longer treatment duration are needed to determine if metformin can prevent diabetes in OSA patients.

Disclosure
S. Rodrigues: None. W.S. Dantas: None. R.A. Beyl: None. R.C. Hebert: None. I. Griffith: None. M. Tanksley: None. E.C. Mader: None. J.P. Kirwan: None. C.L. Axelrod: None. E. Ravussin: Research Support; Eli Lilly and Company, Novartis AG. Advisory Panel; Novartis. P. Singh: None.

Funding
National Institutes of Health (P30DK072476, U54GM104940); CAPES (88887.470405/2019-00 to S.R.)
734-P: High Pancreatic-Derived Factor Level Is Relative to a Lower Remission of Early Postpartum Impaired Glucose Tolerance in Women with History of Gestational Diabetes Mellitus
Authors: PEI LING , LAI FENGHUA , CHEN WENZHAN , CHEN NAN , ZENG RUI , YUE SHUFAN , LI ZETING , WANG CHENXUE , CAO XIAOPEI 
Published: June 2023

Purpose: To clarify whether pancreatic derived factor (PANDER) predicted the remission of early postpartum impaired glucose tolerance (IGT) by lifestyle intervention among women with history of gestational diabetes mellitus (GDM).
Methods: IGT women with GDM history in a prospective cohort study were enrolled at postpartum 4-12 weeks. Subjects were grouped based on quarters of PANDER level at recruitment. After lifestyle intervention, the oral glucose tolerance test (OGTT) was performed and insulin levels were measured at one year postpartum. The relation between PANDER and glycemic outcome was analyzed with logistic regression and receiver operating characteristic curve (ROC).
Results: A total of 113 women were included. 55 (48.7%) of these IGT women were reversed to normal glucose tolerance at one year postpartum by lifestyle intervention. The odds of remission were lower in participants with high PANDER level than in those with low PANDER level. Compared those with PANDER&lt;3.19ng/mL, women with PANDER&gt;5.34 ng/mL, and PANDER&gt;8.77ng/mL, were associated with a lower effect on remission of IGT (OR=0.31, 95%CI 0.11-0.90, P=0.031 and OR=0.12, 95%CI 0.04-0.41, P=0.001, respectively). After adjusting for other confounders, these associations remained in multivariable logistic regression. The area under the receiver operating characteristic curve (AUC) of PANDER for the remission of IGT was 0.702 (95% CI 0.595-0.809). When PANDER was combined with clinical information, the AUC reached 0.812 (95% CI 0.725-0.899) (P&lt;0.001).
Conclusions: High PANDER level in early postpartum was closely associated with the remission of IGT by lifestyle intervention in women with GDM history at one year postpartum.

Disclosure
L.Pei: None. F.Lai: None. W.Chen: None. N.Chen: None. R.Zeng: None. S.Yue: None. Z.Li: None. C.Wang: None. X.Cao: None.

Funding
Sun Yat-sen University (2017001); Science and Technology Foundation of Guangzhou City (201803010101)